EAU 2024 - Results from #40

Viewing 41-60 of 111 articles

EAU 2024: A Prospective, Comparative, Within-Patient Controlled Multicenter Phase III Study Comparing Blue Light Cystoscopy Versus White Light Cystoscopy for the Detection of Bladder Cancer Using Modern HD 4K Equipment

EAU 2024: Risk Adapted Screening for Prostate Cancer in Europe: PSA + Risk Calculators + MRI (The EAU Screening Algorithm)

EAU 2024: Non-Thermal Atmospheric Plasma Ablation for Intermediate Risk Non-Muscle Invasive Bladder Cancer: A First in Human Trial

EAU 2024: Is There a Role for BCG in Very High-Risk Non-Muscle Invasive Bladder Carcinoma? Multicenter Analysis of Oncological Outcomes and Risk Dynamics

EAU 2024: Subsequent Therapies After Intravesical BCG in Patients with Bladder Cancer: Analysis of Real-World Treatment Patterns

EAU 2024: PSMA-PET Guided Intensification of Salvage Radiotherapy after Radical Prostatectomy: a Phase 2 Randomized Controlled Trial

EAU 2024: Intravesical Administration of Durvalumab to Patients with High Risk Non-Muscle Invasive Bladder Cancer Who Experience BCG Failure. Final Results from a Phase II Study by the Hellenic GU Cancer Group

EAU 2024: The International Bladder Cancer Group Intermediate-Risk Non-Muscle Invasive Bladder Cancer (IBCG IR-NMIBC) Scoring System Predicts the Need for Intervention for Patients on Active Surveillance

EAU 2024: Three-Year Oncological Outcomes of the Randomized Phase II Trial ARNEO: Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-Risk Prostate Cancer

EAU 2024: PSICHE Trial: PSMA Guided Approach for Biochemical Relapse After Prostatectomy- a Prospective Trial

EAU 2024: Two-Year Quality of Life (QoL) Outcomes of the Randomized Phase II Trial ARNEO: Neoadjuvant Degarelix with or without Apalutamide Prior to Radical Prostatectomy for High-Risk Prostate Cancer

EAU 2024: Does Audit, Feedback and Education Improve Quality Indicator Achievement and Reduce Early Recurrence Rates in TURBT Surgery for NMIBC? Results from the RESECT Cluster Randomised Trial

EAU 2024: Identifying the Optimal Definition of PSA Response After Metastasis Directed Therapy in Men with Oligo-Recurrent Prostate Cancer Detected at PSMA PET

EAU 2024: First Results of the Phase Ib-II BladderGATE Clinical Trial: Intravenous Atezolizumab + Intravesical Bacillus Calmette-Guérin (BCG) Upfront Combination in BCG-Naïve High Risk Non-Muscle Invasive Bladder Cancer Patients

EAU 2024: Outpatient Laser Coagulation of Low-Grade Intermediate Risk Bladder Tumor Compared with TURBT, 12 Months and Long-Term Follow-up of a Noninferiority RCT

EAU 2024: A Phase II Clinical Trial of Neoadjuvant Sasanlimab and Stereotactic Body Radiation Therapy as an in Situ Vaccine for Cisplatin Ineligible Muscle Invasive Bladder Cancer

EAU 2024: Challenging the Paradigm of BCG Unresponsive Bladder Cancer: Does Additional BCG Have an Effect?

EAU 2024: Avoiding Overtreatment using PSA Doubling Time Kinetics: Long-Term Management of BCR Following RARP

EAU 2024: PIONEER: Development of a Predictive Model for Death Amongst Patients with mHSPC Treated with One of the Approved Treatment Plans Based on Characteristics Present at Admission Using Big Data

EAU 2024: Efficacy of Intravesical Nadofaragene Firadenovec-Vncg for Patients with BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: 36-Month Follow-up from a Phase 3 Trial

1
2
3
4
5
6